Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Psorizide Ultra is a homeopathic oral prescription medication developed by Plymouth Pharmaceuticals for the treatment of moderate to severe inflammatory skin conditions, including eczema, atopic dermatitis, seborrheic dermatitis, and seborrhea. The formulation is composed of natural mineral compounds, typically including nickel sulfate, potassium bromide, fumaric acid, and zinc sulfate, prepared at homeopathic dilutions. It is designed to be taken orally to address systemic factors contributing to skin inflammation. As a homeopathic product, Psorizide Ultra does not have a described conventional molecular mechanism of action or a specific biochemical target; instead, it operates based on homeopathic principles of mineral-based therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Psorizide Ultra.